论文部分内容阅读
目的:探索支持-表达性团体干预对改善肺癌化疗患者述情障碍的效果。方法:采用抛硬币法将两个病区的62肺癌化疗患者分为对照组和干预组，干预组32例，对照组30例，干预组采用支持-表达性团体干预并沿用行动研究法完善干预路径进行6周干预，对照组无特殊干预，干预前、干预后及干预后1个月两组采用多伦多述情障碍量表、医院焦虑抑郁量表进行测量，采用SPSS 21.0进行数据统计分析。结果:广义估计方程显示，情感识别障碍(Waldn 组间χn 2＝6.055, Waldn 交互χn 2＝15.157)、情感描述障碍(Waldn 组间χn 2＝5.736, Waldn 交互χn 2＝28.912)、述情障碍(Waldn 组间χn 2＝7.181，Waldn 交互χn 2＝28.126)、焦虑(Waldn 组间χn 2＝4.905，Waldn 交互χn 2＝30.491)、抑郁(Waldn 组间χn 2＝9.580，Waldn 交互χn 2＝29.417)、焦虑抑郁(Waldn 组间χn 2＝8.140，Waldn 交互χn 2＝47.851)的组间效应和交互效应显著(均n P0.05)，时间效应(Waldn 时间χn 2＝6.381，n P<0.05)和交互效应(Waldn 交互χn 2＝6.339，n P<0.05)显著。情感识别障碍、情感描述障碍、述情障碍总分、焦虑、抑郁及焦虑抑郁总分在干预完成时和干预完成后的组别效应显著(均n P<0.05)。与干预前相比，干预组述情障碍总分[(52.94±4.77)分、(52.06±4.07)分]、情感识别障碍[(17.72±2.23)分、(17.78±1.64)分]、情感描述障碍[(13.44±1.94)分、(13.41±1.79)分]、焦虑抑郁总分[(14.41±2.63)分、(13.75±2.97)分]、焦虑[(7.03±1.64)分、(6.84±1.51)分]、抑郁[(7.38±1.45)分、(6.91±1.75)分]在干预后完成时、干预后1个月均有降低(n P<0.05)，而对照组评分仅焦虑抑郁总分在干预完成时有所降低(n P<0.05)。n 结论:支持-表达性团体干预可降低肺癌化疗患者述情障碍水平，对改善存在情绪认知功能障碍、情绪躯体症状识别障碍的肺癌化疗患者焦虑、抑郁具有积极意义。“,”Objective:To explore the effect of supportive-expressive group therapy (SEGT) on alexithymia in patients with lung cancer.Methods:Totally 62 lung cancer patients were divided into control group(n n=30) and intervention group(n n=32) by coin flipping method.The intervention group received 6-week supportive-expressive group therapy and the intervention path was improved by action research method.There was no special intervention in the control group.The Toronto alexithymia scale (TAS-20) and hospital anxiety and depression scale (HADS) were used for measurement, and statistical analysis was carried out by SPSS 21.0.n Results:The emotional recognition disorder (Waldn groupχn 2=6.055, Waldn interactionχn 2=15.157), emotional description disorder (Waldn groupχn 2=5.736, Waldn interactionχn 2=28.912), TAS-20 (Waldn groupχn 2=7.181, Waldn interactionχn 2=28.126), anxiety (Waldn groupχn 2=4.905, Waldn interactionχn 2=30.491), depression (Waldn groupχn 2=9.580, Waldn interactionχn 2=29.417) and HADA (Waldn groupχn 2=8.140, Waldn interactionχn 2=47.851) had significant group effect and interaction effect at the pre-test, post-test and 1 month after intervention(all n P0.05), but the time effect (Waldn timeχn 2=6.381, n P<0.05) and the interaction effect (Waldn interactionχn 2=6.339, n P<0.05) were significant in the three time points.The group effect of emotional recognition disorder, emotional description disorder, TAS-20, anxiety, depression and HADA score at completed intervention and 1 month after intervention were significant(alln P<0.05). Compared with before intervention, TAS-20((52.94±4.77) , (52.06±4.07)), emotional recognition disorder((17.72±2.23) , (17.78±1.64)), emotional description disorder((13.44±1.94) , (13.41±1.79)), HADA((14.41±2.63) , (13.75±2.97)), anxiety ((7.03±1.64), (6.84±1.51)), depression ((7.38±1.45) , (6.91±1.75) ) at completed intervention and 1 month after intervention decreased (n P<0.05), while the HADS of control group only decreased at completed intervention (n P<0.05).n Conclusion:SEGT can reduce alexithymia in lung cancer receiving chemotherapy, and this intervention has positive effect on improving anxiety and depression in lung cancer patients received chemotherapy who are accompanied with emotional cognitive impairment and emotional somatic symptom recognition disorder.